AstraZeneca plc (AZN) Ordinary US$0.25
229.00p
(2.96%)
- Add to watchlist
- Create an alert
- This stock can be held in a
229.00p
(2.96%)
Deal for just £11.95 per trade in a
Stocks and Shares ISA,
Lifetime ISA
,
SIPP
or
Fund and Share Account
229.00p
(2.96%)
Deal for just £11.95 per trade in a
Stocks and Shares ISA,
Lifetime ISA
,
SIPP
or
Fund and Share Account
Share news, reports & tips
-
AstraZeneca sells cholesterol drug rights for up to $350m
1 December 2020 07:41
(Sharecast News) - AstraZeneca said it had agreed to sell the rights to its cholesterol treatment Crestor to Germany's Grunenthal for up to $350m (£261m).
-
AstraZeneca's 'Forxiga' gets approval in Japan for heart failure
30 November 2020 07:43
(Sharecast News) - AstraZeneca announced on Monday that 'Forxiga', or dapagliflozin, has been approved in Japan for the treatment of patients with chronic heart failure, who are receiving...
-
Friday broker round-up
27 November 2020 13:18
(Sharecast News) - GoCo: Deutsche Bank downgrades to hold with a target price of 1,974p.
-
Europe close: Stocks give back early gains
23 November 2020 17:23
(Sharecast News) - European shares pared early gains on Monday even after positive news around AstraZeneca's Covid-19 vaccine.
-
Proof of Covid-19 vaccination may be required for travel, says Qantas
23 November 2020 14:05
(Sharecast News) - International passengers will only be able to travel on Qantas flights if they have been vaccinated against Covid-19, the airline's chief executive has suggested.
-
Monday broker round-up
23 November 2020 13:28
(Sharecast News) - DWF Group: Liberum initiates at hold with a target price of 90p.
-
AstraZeneca Covid-19 vaccine proves effective
23 November 2020 07:02
(Sharecast News) - AstraZeneca said its Covid-19 vaccine was highly effective in preventing the virus and that it would move quickly to get approval for use.
-
Unions call for frontline workers to have priority access to Covid-19 vaccine
20 November 2020 08:22
(Sharecast News) - UK unions called for key frontline workers to be given priority access for a Covid-19 vaccine once its rolled out after they were omitted from the list.
-
AstraZeneca gets US approval for additional Imfinzi dosing option
20 November 2020 07:33
(Sharecast News) - AstraZeneca announced on Friday that 'Imfinzi', or durvalumab, has been approved in the US for an additional dosing option - a 1,500mg fixed dose every four weeks in the approved...
-
Berenberg stays at 'buy' on AstraZeneca, positive on antibody treatment
19 November 2020 11:10
(Sharecast News) - Analysts at Berenberg struck a positive note on AstraZeneca shares after the drugmaker published full immunogenicity data earlier in the session for its Covid-19 vaccine candidate, AZD 1222.
-
AstraZeneca vaccine shows promise among elderly
19 November 2020 09:13
(Sharecast News) - AstraZeneca's potential Covid-19 vaccine showed a strong immune response in older people, suggesting it may protect some of those most susceptible to the virus, trial data showed.
-
Pfizer Covid-19 vaccine more than 94% effective in older adults
18 November 2020 12:09
(Sharecast News) - The Covid-19 vaccine candidate being developed by Pfizer and BioNTech has shown an elevated degree of efficacy in preventing Covid-19 among those aged 65 and over.
Company announcements Announcements
-
Total Voting Rights
1 December 2020 15:00
AstraZeneca
-
Block listing Interim Review
1 December 2020 15:00
AstraZeneca
-
Crestor to be divested to Grünenthal in Europe
1 December 2020 07:00
AstraZeneca
-
Forxiga approved in Japan for heart failure
30 November 2020 07:00
AstraZeneca
-
AZD1222 vaccine effective against COVID-19
23 November 2020 07:00
AstraZeneca
-
Imfinzi new dosing approved in the US
20 November 2020 07:00
AstraZeneca
-
Tezepelumab Phase III trial met primary endpoint
10 November 2020 07:00
AstraZeneca
-
Calquence approved in the EU for CLL
9 November 2020 07:00
AstraZeneca
-
Brilinta approved in the US in stroke
6 November 2020 07:00
AstraZeneca
-
Lynparza approved in the EU for wider ovarian use
5 November 2020 07:15
AstraZeneca
-
Lynparza approved in the EU for prostate cancer
5 November 2020 07:10
AstraZeneca
-
Forxiga approved in the EU for heart failure
5 November 2020 07:05
AstraZeneca
Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. This news service is operated by Digital Look Ltd. Republication or redistribution of Digital Look Ltd content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Digital Look Ltd. Please see https://www.sharecast.com/newsfeedterms/index.html for our terms and conditions.
© Digital Look Ltd 1998-2020. All rights reserved.
Deal for just £11.95 per trade in a
Stocks and Shares ISA,
Lifetime ISA
,
SIPP
or
Fund and Share Account
The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.
Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.